These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31484540)

  • 21. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
    Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
    Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.
    Verdanet E; Dereure O; René C; Tempier A; Benammar-Hafidi A; Gallo M; Frouin E; Durand L; Gazagne I; Costes-Martineau V; Cacheux V; Szablewski V
    Histopathology; 2017 Oct; 71(4):648-660. PubMed ID: 28594133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.
    Jiang CY; Yu JJ; Ruan Y; Wang XH; Zhao W; Wang XJ; Zhu YP; Gao Y; Hao KY; Chen L; Han BM; Xia SJ; Zhao FJ
    Oncotarget; 2016 May; 7(18):26247-58. PubMed ID: 27028859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-grade B-cell lymphoma with 11q aberration in the HIV setting: a clinicopathological study of 10 cases and literature review.
    Chang J; Liang Y; Gao Y; Wu M; Lv F; Liu H; Sun L; Yue Z; Meng L; Zhang Y; Jin M
    Infect Agent Cancer; 2024 Sep; 19(1):42. PubMed ID: 39261841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
    Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
    J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
    Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
    Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
    Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
    Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
    Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of LMO2 protein in acute B-cell and myeloid leukemia.
    Cobanoglu U; Sonmez M; Ozbas HM; Erkut N; Can G
    Hematology; 2010 Jun; 15(3):132-4. PubMed ID: 20557670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of LIM domain only 2 (LMO2) in chronic myelogenous leukaemia.
    Atay MH; Ozatli D; Kelkitli E; Yildiz L; Turgut M; Guler N; Toptas T
    Histopathology; 2013 Aug; 63(2):293-4. PubMed ID: 23879574
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.
    Vazquez I; Papaleo N; Garcia E; Salido M; Salar A; Hernandez S; Calvo X; Colomo L
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong BCL2 expression in Burkitt lymphoma is not uncommon in adults.
    Pervez S; Raza MQ; Mirza A; Pal A
    Indian J Pathol Microbiol; 2011; 54(2):290-3. PubMed ID: 21623076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue.
    Masqué-Soler N; Szczepanowski M; Kohler CW; Aukema SM; Nagel I; Richter J; Siebert R; Spang R; Burkhardt B; Klapper W
    Br J Haematol; 2015 Nov; 171(4):501-8. PubMed ID: 26218299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bright CD38 expression is an indicator of MYC rearrangement.
    Maleki A; Seegmiller AC; Uddin N; Karandikar NJ; Chen W
    Leuk Lymphoma; 2009 Jun; 50(6):1054-7. PubMed ID: 19455464
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma.
    Karnik T; Ozawa MG; Lefterova M; Luna-Fineman S; Alvarez E; Link M; Zehnder JL; Arber DA; Ohgami RS
    Hum Pathol; 2015 Apr; 46(4):629-33. PubMed ID: 25701230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.
    Wu J; Shi C; Li H; Song W; Huang S; Zhang J; Li W; Li Z; Zhang M
    BMC Med; 2023 Jul; 21(1):253. PubMed ID: 37442994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.